Browsing Tag
AbbVie
78 posts
AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra
AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company…
Xilio Therapeutics accelerates cancer immunotherapy with new masked T cell engager programs and $52m AbbVie collaboration
Xilio Therapeutics, Inc., a clinical-stage biotechnology company based in Waltham, Massachusetts, has announced the development of three new…
FDA approves EMBLAVEO to combat complicated intra-abdominal infections with limited treatment options
The U.S. Food and Drug Administration (FDA) has granted approval for EMBLAVEO (aztreonam and avibactam), marking a significant…
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics,…
Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma
Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab…
AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top
Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials…
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The…
NImmune Biopharma collaborates with BioTherapeutics on next-gen precision medicines
NImmune Biopharma has entered into a strategic partnership with BioTherapeutics, a clinical-stage biotech company based in Virginia, to…
AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing…